Navigation Links
Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
Date:9/27/2010

SAN DIEGO, Sept. 27 /PRNewswire-FirstCall/ -- Amira Pharmaceuticals, Inc. announced today that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for AM152, a novel LPA1 antagonist.  If accepted, the IND will enable Amira to begin Phase 1 safety studies with the compound in healthy subjects.

"We believe the pre-clinical data obtained to date for AM152 demonstrate characteristics which warrant further studies in humans to determine its potential utility in various fibrotic diseases," said Isabelle DeArmond, Vice President, Clinical Development. "The safety and pharmacokinetic data obtained from Phase 1 studies are an important first step in the clinical investigation of this program."

Added Bob Baltera, Chief Executive Officer, "We are extremely excited to reach this point with our LPA1 program. There have recently been numerous papers published describing the novel biology of the LPA1 receptor and how it relates to abnormal fibrotic processes.  We have worked hard to develop this program and look forward to learning more about this potential therapeutic candidate in a clinical setting."

While there are no LPA1 selective antagonists approved for therapeutic use, there is a strong scientific rationale for this target to be a novel treatment in various fibrotic diseases, including scleroderma and idiopathic pulmonary fibrosis.

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases.  Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase-activating protein) inhibitors in respiratory and cardiovascular disease.

Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair®. The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future.  For more information, visit www.amirapharm.com.


'/>"/>
SOURCE Amira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotechs Annual Fierce 15
2. Visage Imaging Releases Amira 5.3
3. Amira Announces AM103 and AM803 Patent Grant in the United Kingdom
4. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
5. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
6. Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
7. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amiras Lead DP2 Antagonist, AM211
8. Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461
9. Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference
10. Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S.
11. Lotus Pharmaceuticals Announces Two Senior Management Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... Treato , the single ... today that it has been named a Cool Vendor ... Life Sciences, 2016, Stephen Davies , ... on life-science- oriented analytics, algorithms and smart machine technology ... confirm medication ingestion, and analyze unstructured information.   ...
(Date:4/28/2016)... 2016 Dr. Vivek Ahuja , ... Ste phen Schmidt ... provider of cloud-based software solutions for life sciences, today announced key ... a wealth of insight to a growing business.  This will bolster ... George Phillips joined ArisGlobal in the position of Vice ...
(Date:4/28/2016)...   Acsis , a leading provider of supply ... research and advisory firm IDC has named it a ... Pharmaceutical Track and Trace Software 2016 Vendor Assessment (doc ... of the capabilities and business strategies of 10 vendors ... Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
Breaking Medicine Technology:
(Date:5/3/2016)... FL (PRWEB) , ... May 03, 2016 , ... Branches, ... both its Grow & Climb children and youth programs in South Miami. Macy’s is ... years. , The Grow Program provides afterschool tutoring, mentoring, enrichment and academic support ...
(Date:5/3/2016)... ... 03, 2016 , ... The new web-based solution HIPAA ... practices, to better grasp and implement HIPAA’s privacy, security, and data breach requirements. ... well-defined, expert-created path to compliance. HIPAA Institute has positioned itself to be an ...
(Date:5/2/2016)... , ... May 02, 2016 , ... It has just ... the keynote speaker for five events throughout the month of May. , Uldrich is ... of national news outlets. He also frequently appears on the Science Channel’s FutureScape and ...
(Date:5/2/2016)... ... May 02, 2016 , ... Pets bring laughter, joy and love into ... owners celebrate National Pet Week, which falls on the first full week of May. ... cherish the human-animal bond and recognize responsible pet ownership. Pet owners can live out ...
(Date:5/2/2016)... ... May 02, 2016 , ... “Engineering Bubbles,” an oil painting submitted by ... Art Forum held recently at the Annual Meeting in Los Angeles. The first annual ... members and Annual Meeting attendees. , “Through art I hope to educate ...
Breaking Medicine News(10 mins):